Program
olatorepatide
Also written as “Olatorepatide”, “HS-20094” and “HS-20094 Injection”.
Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hidradenitis Suppurativa · Overweight, led by 2 companies.
Drug pageOlatorepatide: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Groupits history only | 83 open or running | phase 3since Feb 18, 2025 | Oct 29, 2021 | Mar 30, 2027phase 3 · NCT07156500 |
| Regeneron Pharmaceuticals | 44 open or running | phase 3since Oct 19, 2026 | Feb 18, 2026 | Jan 21, 2028phase 2 · NCT07685808 |
- Named in Hansoh Pharmaceutical Group’s own pipeline as
Olatorepatide (HS-20094)
, phase 4, as of Aug 26, 2026 (source).
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseRegeneron licensed it from Hansoh, for everywhere outside mainland China, Hong Kong and Macau.Announced Jun 2, 2025 · Source: Regeneron, Jun 2, 2025
History and studies of Regeneron Pharmaceuticals only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Feb 29, 2024Named olatorepatideINNProposed as its International Nonproprietary Name in WHO's List 130 · before, HS-20094
- Jun 2, 2025Regeneron licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong and Macau · announced · Regeneron
- Feb 18, 2026First study: phase 2 study in OverweightFirst studyNCT07431086 · 120 enrolled · United States
- Jun 29, 2026Phase 2 study in OverweightNCT07685808 · 360 planned · United States
- Sep 15, 2026Phase 2 study in Hidradenitis SuppurativaNCT07830329 · 300 planned · United States
- Oct 19, 2026Phase 3 study in OverweightPhase 3 reachedNCT07896265 · 3,000 planned
Ahead
- Nov 13, 2026Primary completion: phase 2 study in OverweightNCT07431086
- Jan 21, 2028Primary completion: phase 2 study in OverweightNCT07685808
- Nov 24, 2028Primary completion: phase 2 study in Hidradenitis SuppurativaNCT07830329
- Dec 19, 2028Primary completion: phase 3 study in OverweightNCT07896265
TargetBeta
“A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)”study text, read by Claude · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Tirzepatiderule | Eli Lilly | phase 4 | 72 |
| retatrutiderule | Eli Lilly | phase 3 | 33 |
| brenipatide | Eli Lilly | phase 3 | 19 |
| UBT251 | The United Laboratories International | phase 3 | 12 |
| enicepatide | Hoffmann-La Roche | phase 3 | 10 |
| VK2735rule | Viking Therapeutics | phase 3 | 8 |
| NNC0519-0130 | Novo Nordisk | phase 2 | 11 |
| BI 3034701 | Boehringer Ingelheim | phase 2 | 6 |
| HRS-4729 | Jiangsu HengRui Medicine | phase 2 | 5 |
| NA-931rule | biomed-industries-inc | phase 2 | 3 |
Studies
All 4 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07896265Overweight | 3 | Not yet recruiting | Dec 19, 2028 | 3,000 |
| NCT07830329Hidradenitis Suppurativa · United States | 2 | Recruiting | Nov 24, 2028 | 300 |
| NCT07685808Overweight · United States | 2 | Recruiting | Jan 21, 2028 | 360 |
| NCT07431086Overweight · United States | 2 | Active, not recruiting | Nov 13, 2026 | 120 |
How it is read
Names in the registry
- “Olatorepatide”, 4 entries
- “HS-20094”, 3 entries
- “HS-20094 Injection”, 3 entries
- “HS-20094 injection”, 1 entry
- “HS-20094 5mg”, 1 entry
Codes read as this program: HS20094.
Conditions, from the studies’ own filings
- Obesity, 5 studies
- Diabetes Mellitus, Type 2, 5 studies
- Hidradenitis Suppurativa, 1 study
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.